Dyne Therapeutics Stock Book Value Per Share
| DYN Stock | USD 29.69 0.04 0.13% |
Dyne Therapeutics fundamentals help investors to digest information that contributes to Dyne Therapeutics' financial success or failures. It also enables traders to predict the movement of Dyne Stock. The fundamental analysis module provides a way to measure Dyne Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dyne Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.53 | 1.45 | |
| Tangible Book Value Per Share | 1.53 | 1.45 |
Dyne | Book Value Per Share |
Dyne Therapeutics Company Book Value Per Share Analysis
Dyne Therapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Dyne Therapeutics Book Value Per Share | 6.93 X |
Most of Dyne Therapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dyne Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Dyne Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Dyne Therapeutics is extremely important. It helps to project a fair market value of Dyne Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Dyne Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Dyne Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Dyne Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
Dyne Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of Dyne Therapeutics is about 6.934 times. This is 507.88% lower than that of the Biotechnology sector and 102.79% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.64% higher than that of the company.
Dyne Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dyne Therapeutics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dyne Therapeutics could also be used in its relative valuation, which is a method of valuing Dyne Therapeutics by comparing valuation metrics of similar companies.Dyne Therapeutics is currently under evaluation in book value per share category among its peers.
Dyne Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Dyne Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Dyne Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Dyne Fundamentals
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 2.32 B | ||||
| Shares Outstanding | 101.77 M | ||||
| Shares Owned By Insiders | 0.48 % | ||||
| Shares Owned By Institutions | 99.52 % | ||||
| Number Of Shares Shorted | 9.94 M | ||||
| Price To Earning | 35.58 X | ||||
| Price To Book | 4.28 X | ||||
| EBITDA | (233.48 M) | ||||
| Net Income | (235.94 M) | ||||
| Cash And Equivalents | 291.84 M | ||||
| Cash Per Share | 5.64 X | ||||
| Total Debt | 27.41 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 11.63 X | ||||
| Book Value Per Share | 6.93 X | ||||
| Cash Flow From Operations | (188.16 M) | ||||
| Short Ratio | 12.11 X | ||||
| Earnings Per Share | (3.58) X | ||||
| Price To Earnings To Growth | 0.19 X | ||||
| Target Price | 51.4 | ||||
| Number Of Employees | 173 | ||||
| Beta | 1.1 | ||||
| Market Capitalization | 3.02 B | ||||
| Total Asset | 165.08 M | ||||
| Retained Earnings | (632.51 M) | ||||
| Working Capital | 78.28 M | ||||
| Current Asset | 1.93 B | ||||
| Current Liabilities | 809 M | ||||
| Net Asset | 165.08 M |
About Dyne Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dyne Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dyne Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dyne Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Dyne Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dyne Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dyne Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Dyne Stock
Moving against Dyne Stock
| 0.5 | NXGLW | NexGel Warrant | PairCorr |
| 0.38 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.34 | KZR | Kezar Life Sciences | PairCorr |
| 0.33 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.33 | RNXT | RenovoRx | PairCorr |
The ability to find closely correlated positions to Dyne Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dyne Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dyne Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dyne Therapeutics to buy it.
The correlation of Dyne Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dyne Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dyne Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dyne Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Dyne Therapeutics Piotroski F Score and Dyne Therapeutics Altman Z Score analysis. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne Therapeutics. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.58) | Return On Assets (0.40) | Return On Equity (0.69) |
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.